 "Caplin Point receives EU GMP nod for sterile injectable facility in Chennai")
Caplin Point has received EU GMP approval for its small volume sterile injectable liquids facility at Chennai. The facility, which was inspected by the EU authorities in March 2015, is capable of manufacturing liquid injectables in vials, ampoules, lyophilised vials and ophthalmic dosages.
C C Paarthipan, chairman, Caplin Point, said, "This is our first approval and we are expecting more regulatory GMP approvals in future. The global injectable market is projected to grow to $ 70 billion by 2020 and is frequently plagued by shortages. This presents an exciting opportunities for us to carve out a niche."
EU approval grants access not only to European Union, but also several other countries in the regulated domain through mutual recognition process, said the company.
Caplin Point is a niche pharmaceutical company with a unique business model catering predominately to emerging markets of Latin America and Africa. The company has also recently added soft gelatin capsules, suppositories and carbapenem lines to its existing facilities for emerging markets.
C C Paarthipan, chairman, Caplin Point, said, "This is our first approval and we are expecting more regulatory GMP approvals in future. The global injectable market is projected to grow to $ 70 billion by 2020 and is frequently plagued by shortages. This presents an exciting opportunities for us to carve out a niche."
EU approval grants access not only to European Union, but also several other countries in the regulated domain through mutual recognition process, said the company.
Caplin Point is a niche pharmaceutical company with a unique business model catering predominately to emerging markets of Latin America and Africa. The company has also recently added soft gelatin capsules, suppositories and carbapenem lines to its existing facilities for emerging markets.